In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry

• DOI: 10.1007/s15010-024-02176-2
• Publication Date: 2024-02-07T06:02:20Z
• Authors: Silvano Esposito; Pasquale Pagliano; Giuseppe De Simone; Amedeo Guarino; Angelo Pan; Paola Brambilla; Claudio Mastroianni; Miriam Lichtner; Pierluigi Brugnaro; Anna Carretta; Teresa Santantonio; Gaetano Brindicci; Giuliana Carrega; Francesca Montagnani; Giuseppe Lapadula; Anna Spolti; Roberto Luzzati; Elisabetta Schiaroli; Vittoria Scaglione; Carlo Pallotto; Danilo Tacconi; Francesco Quintieri; Enrico Trecarichi
• Keywords: Dalbavancin; Tolerability

Abstract Purpose Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy other off-label indications requiring prolonged intravenous antibiotic administration. Methods We conducted a prospective nationwide study use in real-life settings both analysing each case clinical microbiological characteristics infection safety treatments. Results During period (from December 2018 to July 2021), ID specialists from 14 different centres enrolled 223 patients treated with [141 males (63%) 82 females (37%); male/female ratio 1.72; mean age 59 (SD 17.2) years, (range 15–96). Most population (136/223; 61.0%) came community rather than health care facilities most them were visited Infectious Diseases wards (93/223; 41.7%) clinics (55/223; 24.7%) even though some cured settings, such surgery (18/223; 8.1%), orthopaedic (11/223; 4.9%), Emergency Rooms (7/223; 3.1%) non-surgical (6/223; 2.7%). The common diagnoses osteomyelitis (44 cases/223; 19.7%; which 29 acute 15 chronic osteomyelitis), cellulitis (28/223; 12.5%), cutaneous abscess (23/223; 10.3%), prosthesis-associated (22/223; 9.9%), surgical site (20/223; 9.0%) septic arthritis (15/223; 6.7%). Conclusion In conclusion, by virtue PK/PD properties, represents valuable option daily in-hospital or outpatient antimicrobial regimens also Gram-positive infections.